% of Cases treated with Chemotherapy
| Country average (population) | Country average (country) | England | Scotland | Wales1 | Northern Ireland | Republic of Ireland | |
|---|---|---|---|---|---|---|---|
| All invasive xnmsc | 27.4% | 25.5% | 27.9% | 24.6% | 26.7% | 22.9% | |
| All xnmsc 0-24 | 64.5% | 60.4% | 65.3% | 63.7% | 61.9% | 50.9% | |
| All xnmsc 25-59 | 41.5% | 41.0% | 41.5% | 41.8% | 42.3% | 38.4% | |
| All xnmsc 60-79 | 28.2% | 25.5% | 28.9% | 24.0% | 27.6% | 21.4% | |
| All xnmsc 80+ | 8.8% | 6.9% | 9.2% | 5.5% | 8.3% | 4.8% | |
| Haematology | 54.1% | 47.0% | 55.0% | 56.1% | 51.6% | 25.3% | |
| Head and Neck | 30.4% | 27.3% | 31.2% | 25.3% | 33.6% | 19.0% | |
| Lower GI | 33.9% | 32.3% | 34.3% | 31.5% | 34.2% | 29.3% | |
| Upper GI | 40.7% | 40.9% | 41.3% | 34.5% | 40.0% | 47.7% | |
| HPB | 25.7% | 23.4% | 26.7% | 15.9% | 24.3% | 26.9% | |
| Trachea, Bronchus & Lung | 26.9% | 23.9% | 28.2% | 18.3% | 28.4% | 20.9% | |
| Melanoma of skin | 1.3% | 1.4% | 1.4% | 0.3% | 2.0% | 1.7% | |
| Breast | 32.6% | 32.0% | 32.8% | 30.8% | 32.3% | 32.1% | |
| Cervix | 38.0% | 42.4% | 37.1% | 42.8% | 41.2% | 48.5% | |
| Other Female Genitals | 30.1% | 29.5% | 30.2% | 31.1% | 28.5% | 28.0% | |
| Prostate | 7.2% | 6.9% | 7.2% | 8.4% | 6.1% | 5.8% | |
| Kidney | 9.3% | 8.9% | 9.7% | 3.3% | 13.5% | 9.0% | |
| Bladder | 32.3% | 27.8% | 33.2% | 26.3% | 32.5% | 19.0% | |
| Brain and CNS | 38.2% | 35.8% | 38.6% | 39.9% | 32.3% | 32.2% | |
| Thyroid & other endocrine glands | 5.5% | 5.2% | 5.6% | 4.3% | 8.1% | 2.8% | |
| CUP | 11.2% | 8.9% | 11.8% | 9.5% | 9.0% | 5.3% | |
| Other invasive cancer | 29.5% | 27.8% | 29.8% | 28.5% | 26.7% | 26.2% | |
| Breast in situ | 2.2% | 2.5% | 2.2% | 1.3% | 1.4% | 5.3% | |
| Cervix in situ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Other tumours | 14.4% | 11.1% | 15.5% | 12.8% | 9.5% | 6.7% | |
| Non-Melanoma Skin Cancer | 0.1% | 0.3% | 0.1% | 0.5% | 0.1% | 0.5% |